

Electronic Report to the Board

Secretariat's Recommendations on Funding from the COVID-19 Response Mechanism

GF/B45/ER22

Board Decision

Purpose of the paper: This document proposes the following decision point:

GF/B45/EDP27: Approval of the Secretariat's Recommendation on Funding from the 2021 COVID-19 Response Mechanism¹

Document Classification: Internal.

Document Circulation: Board Members, Alternate Board Members, Constituency Focal Points and Committee Members.

This document may be shared by the Focal Points within their respective Board constituency. The document must not however be subject to any further circulation or otherwise be made public.

¹ The Secretariat recommends the approval of funding from the 2021 COVID-19 Response Mechanism for Indonesia, up to an amount of US\$21,997,697.

Decision

Decision Point: GF/B45/EDP27: Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020), as well as increases to C19RM awards previously approved by the Board that either exceed USD 10 million or include interventions not previously approved by the Board;
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B45/ER22; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

Executive Summary

Context and Input Received

Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (C19RM)

The Secretariat recommends the approval of funding from C19RM for Indonesia, up to an amount of US\$21,997,697.

The country awards in Table 1 are recommended by the Secretariat following internal review processes, which included input from a C19RM Technical Advisory Group of relevant ACT-Accelerator partners (CTAG) and GAC partners.

For each country funding request, the Secretariat reviewed (i) the strategic focus of the investment; (ii) alignment with WHO technical guidance, the C19RM Technical Information Note, the National Strategic Preparedness and Response Plan for COVID-19 and guidance from partners on alignment with the HIV, TB and malaria mitigation plans in the country; (iii) linkages with underlying grants and service disruption for human immunodeficiency virus (HIV), tuberculosis (TB) and malaria programs; (iv) alignment with principles of stakeholder and community engagement, gender equity and human rights; (v) availability of appropriate procurement channels (global availability and sourcing implication of the health products requested to be procured), especially related to supply-side aspects, including the availability of scarce products; (vi) the technical soundness of the request and expected outcomes; (vii) the feasibility and assumptions of proposed activities and the associated budget, including performance and absorption of C19RM 2020 awards; (viii) complementarity/potential duplication with other available sources of funding; (ix) residual risks, including associated fiduciary risks related to implementation arrangements and/or interventions, and mitigating and assurance measures to ensure that funds are used for intended purposes; and (x) value for money.

A list of documents per country to substantiate the Board decision is provided below²:

- C19RM Funding Request;
- C19RM budget (as revised for final recommendation for Board approval, if applicable);
- List of health products (as revised, if applicable);
- National Strategic Preparedness and Response Plan for COVID-19 and budget; and
- Other essential support documents of the C19RM Funding Request:
 - Quantification or needs assessment for COVID-19 health products;
 - COVID-19 National Testing Strategy (where available);
 - C19RM Health Product Management Template (HPMT);
 - C19RM Funding Landscape Table;
 - HIV, TB and malaria program mitigation plans (where relevant);
 - Civil Society suggestions for inclusion in the C19RM Full Funding Request.

All relevant documents containing the Secretariat's reasons for its recommendation to the Board have been made available on the Governance Extranet and are accessible through [this link](#) for Indonesia.

Input Sought

The Board is requested to review the Secretariat recommendation and approve, on a 'no objection' basis, the decision point GF/B45/EDP27.

² The following documents are not required to be submitted for C19RM 2021 Supplementary Funding Requests: National Strategic Preparedness and Response Plan for COVID-19; COVID-19 National Testing Strategy; C19RM Funding Landscape Table; HIV, TB and malaria program mitigation plans; and Civil Society suggestions, on the basis that these were provided alongside the C19RM Full Funding Requests. For Indonesia, all such documents were provided to the Board under GF/B45/ER13.

Table 1: Secretariat's Recommendation on Funding from C19RM³

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country/ Multicountry	Grant name	Currency	C19RM 2020 carry-over amount ⁴	Previously approved C19RM 2021 award ⁵	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020- 2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
Indonesia	IDN-T-MOH	US\$	0	65,811,909 ⁶	21,997,697 ⁷	87,809,606	29.9%	87,809,606	5,456,433

³ The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

⁴ Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

⁵ This includes Secretariat approved Fast-track and Full Funding awards for all grants, as well as awards previously approved by the Board.

⁶ This amount includes US\$15,316,626 C19RM 2021 Fast-track award and US\$50,495,283 C19RM 2021 Full Funding award.

⁷ This amount represents the total C19RM Supplementary Funding requested by Indonesia since the C19RM award previously approved by the Board pursuant to GF/B45/EDP14.

Summary of the Secretariat's Funding Recommendations

Indonesia: Directorate General of Disease Prevention and Control, Ministry of Health of The Republic of Indonesia (IDN-T-MOH)

1.1 Background and context⁸

On 13 August 2021, the Board approved a C19RM Full Funding award of US\$50,495,283 to Indonesia (GF/B45/EDP14) that was focused on the national COVID-19 response, including the strengthening of national laboratories, case management, maintaining essential health services and systems, as well as infection prevention and control in health facilities, including medical waste management. This award built on Indonesia's US\$15,316,626 C19RM 2021 Fast-track award that focused on investments in COVID-19 diagnostics, personal protective equipment (PPE) and therapeutics. In its consideration of Indonesia's initial Full Funding request, the C19RM Investment Committee confirmed that Indonesia may access up to US\$22,210,413 remaining for immediate award to reach the 30 percent C19RM indicative Qualitative Adjustment ceiling for the country, should the country decide to request for the purchase of additional essential COVID-19 related health products, including oxygen support.

During the period of July-August 2021, Indonesia faced a sharp increase in COVID-19 cases, reaching the peak of 40,270 daily cases on 24 July 2021. While before July 2021 the COVID-19 transmission was mostly limited to Java and Bali islands, there has since been an increase of COVID-19 cases in outer Java. Social restriction policy and accelerated vaccination campaign helped to decrease the transmission; however, the third wave of COVID-19 is still possible. The impact of COVID-19 on HIV, TB and malaria programs remains significant. TB case notifications declined by 42 percent in 2020, malaria testing volumes are only at approximately half of the pre-pandemic level, and the number of people living with HIV on antiretroviral therapy remains very low at 151,000 out of an estimated 540,000 people, or 28 percent. Considering the need for additional investments response in these areas, Indonesia submitted the C19RM 2021 Supplementary Funding Request to the Global Fund.

1.2 Strategic focus and prioritization of C19RM 2021 Supplementary Funding request

Building on other Global Fund investments, including the C19RM 2021 Full Funding and Fast-track awards, this Supplementary Funding Request focuses on case management, clinical operations and therapeutics as well as on epidemiological investigation and contact tracing. The Secretariat recommended the following activities to be prioritized for immediate award:

- Oxygen products: the funding will complement prior C19RM investments for COVID-19 case management through the procurement of oxygen therapy equipment, including three mobile pressure swing absorption (PSA) oxygen generators which, in combination with five such generators financed from the national budget, will be used in seven provinces without access to oxygen generators.
- Genomic sequencing equipment: proposed investments will strengthen Indonesia's epidemic surveillance system allowing decentralized genomic sequencing of COVID-19 cases at eight points of entry outside Java Island and in two referral laboratories in Java Island complementing the equipment procured for the National Institute of Health Research and Development procured through the funding of the C19RM 2021 Full Funding award.
- Molecular diagnosis health products for COVID-19: proposed investments include eight GeneXpert machines with uninterruptible power source (UPS) and printers and 50,000 cartridges for the machines complementing the investments to GeneXpert cartridges from previous C19RM 2021 awards.

⁸ Data and statistics from Indonesia's C19RM 2021 Supplementary Funding request.

- COVID-19 impact mitigation for TB program: proposed investments for bi-directional TB/COVID-19 screening and testing in 50 high burden cities will improve TB test and notification coverage and strengthen COVID-19 surveillance.

Implementation arrangements. The Directorate General of Disease Prevention and Control, Ministry of Health of The Republic of Indonesia will act as the Principal Recipient (PR) of this award. Most of the procurement will be done through the Global Fund's Pooled Procurement Mechanism (PPM)/Wambo.org, except the high flow nasal canulas (HFNC) and oxygen cylinders that will be procured locally in line with the Health Product Segmentation Framework, with the Local Fund Agent (LFA) carrying out pre-award procurement reviews. The GeneXpert XPRESS SARS COV-2 cartridges will also be procured locally following the arrangements of previous C19RM 2021 awards.

C19RM Assurance and Risk Mitigation. Overall, the assurance and risk mitigation measures approved for the C19RM Fast-track and Full Funding awards will also apply to the additional funding proposed for the Indonesia Supplementary Funding Request. In addition, the PR will submit a detailed operational plan regarding the use of genomic sequencing machines.

1.3 C19RM Investment Committee review and recommendations

- GAC and CTAG partners (Partners) found the Indonesia Supplementary Funding Request developed in an inclusive manner and aligned with the NSPRP and WHO technical guidance. Partners highlighted the importance of delivering oxygen to the hard-to-reach provinces and facilities and suggested assuring that the operation and servicing of such oxygen units would also be arranged.
- Partners sought broader details regarding the testing strategy behind the genomic sequencing and bidirectional TB/COVID-19 screening investments. Partners also noted that genomic sequencing investments should be used across disease areas. The Secretariat explained that while Indonesia seems to have passed the peak of the second COVID-19 wave, the resurgence of the pandemic was expected considering the low rate of vaccination and the disruption of the Indonesia health system in islands other than Java. Genome sequencing capacity built for COVID-19 surveillance will also contribute to surveillance of other diseases including TB. Secretariat technical disease advisors confirmed the urgent need to accelerate the implementation of the awards to catch up and mitigate COVID-19 impact to the TB program and that investments from C19RM funding were important in scaling up the bidirectional testing.
- The C19RM Investment Committee highlighted the importance of acute phase preparation and surge planning for the possible third COVID-19 wave in Indonesia and its impact, especially outside Java Island. The C19RM Investment Committee appreciated the robustness of Indonesia's Supplementary Funding Request in this regard and stressed the importance of proposed investments that will also strengthen the mitigation of COVID-19 impact on the TB program complementing those supported by the TB grant and domestic funding.
- The C19RM Investment Committee took note that for the previous investments to mobile oxygen PSA plants, the local procurement price turned out to be higher than currently emerging options on PPM/Wambo.org. Accordingly, PPM/Wambo.org would be used for the procurement of PSA investments with the C19RM supplementary funding.
- The C19RM Investment Committee appreciated Indonesia's experience implementing the procurement of genomic sequencing equipment and welcomed further detail that would be provided related to the planned use of genomic sequencing equipment, without requiring an additional Global Fund review or approval.

Table 2: Budget distribution by priority area

Country/ Multicountry	Mitigate COVID-19 impact on HIV, TB and malaria programs		Reinforce COVID-19 national response		Urgent improvement to health and community systems				Total
	Amount	%	Amount	%	Community, Gender and Rights		RSSH Investments		
	Amount	%	Amount	%	Amount	%	Amount	%	Amount
Indonesia	US\$0	0%	US\$21,997,697	100%	US\$0	0%	US\$0	0%	US\$21,997,697

Table 3: COVID-19 Health Product Categories distribution by investment type

Country ⁹	Diagnostics RDT	Diagnostics PCR	PPE	Therapeutics O2	Therapeutics other	Other ¹⁰
Indonesia	US\$0	US\$995,163	US\$0	US\$9,466,051	US\$3,388,275	US\$8,148,208

⁹ Excluding roll-over amounts from C19RM awards in 2020.

¹⁰ This category includes all Health Products that do not fall into any of the five specific categories, as well as any other non-Health Product interventions.

Document Classification: Internal.

Document Circulation: Board Members, Alternate Board Members, Constituency Focal Points and Committee Members.

This document may be shared by the Focal Points within their respective Board constituency. The document must not however be subject to any further circulation or otherwise be made public.

Annex 1 – Past Decisions

Pursuant to the Governance Plan for Impact as approved at the 32nd Board Meeting,¹¹ the following summary of relevant past decision points is submitted to contextualize the decision point proposed in this paper.

Relevant past Decision Point	Summary and Impact
Decision Point: GF/B45/EDP14: Approval of the Secretariat’s Recommendation on Funding from the COVID-19 Response Mechanism August 2021	The Board approved the Secretariat’s recommendation on funding from the COVID-19 Response Mechanism to Indonesia.
Decision Point: GF/B44/EDP18: Second Extension of C19RM Timeline and Operational Flexibility for COVID-19 ¹² March 2021	The Board approved a further extension of the timelines for the receipt, award, and use of funds for the Global Fund COVID-19 Response Mechanism based on further modifications proposed by the Secretariat.
Decision Point: GF/B43/EDP12: Extension of C19RM Timeline and Operational Flexibility for COVID-19 ¹³ September 2020	The Board approved an extension of the time limit for the award of funds from the Global Fund COVID-19 Response Mechanism.
GF/B42/EDP11: Additional Support for Country Responses to COVID-19 ¹⁴ April 2020	The Board approved operational flexibilities and additional support to countries, including the COVID-19 Response Mechanism, to enable the Global Fund and countries to effectively respond to the negative impact of the COVID-19 pandemic.

¹¹ <https://www.theglobalfund.org/board-decisions/b32-dp05/>.

¹² <https://www.theglobalfund.org/board-decisions/b44-edp18/>.

¹³ <https://www.theglobalfund.org/board-decisions/b43-edp12/>.

¹⁴ <https://www.theglobalfund.org/board-decisions/b42-edp11/>.